CD33 is expressed on the malignant blast cells in most cases of acute myeloid leukemia (AML) but not on normal hematopoietic pluripotent stem cells. Antibody-based therapies for AML have, therefore, focused on CD33 as a suitable tumor-associated target antigen. The most promising results have been obtained with gemtuzumab ozogamicin (GO, Mylotargt), a humanized IgG 4 anti-CD33 monoclonal antibody joined to a calicheamicinc 1 derivative. Engagement of CD33 by GO results in immunoconjugate internalization and hydrolytic release of the toxic calicheamicin moiety, which, in turn, causes DNA damage and cell death. Since 2000, when GO was approved for clinical use, treatment trials and pilot studies have revealed potential expanded applications along with additional limitations. At the same time, correlative biological and in vitro functional studies have further characterized CD33 expression patterns in AML, the significance of CD33-antibody interactions, pathways involved in GO-induced cytotoxicity and potential drug resistance mechanisms. This review summarizes the recent data addressing mechanisms of GO action and discusses their relevance with regard to clinical applications and the limitations of using experimental model systems to mimic in vivo conditions. As the first drug conjugate approved for clinical use, GO serves as an important paradigm for other immunoconjugates against internalizing tumor antigens.
Background
Recently characterized immunophenotypic and molecular pathogenetic features of acute myeloid leukemia (AML) have identified potential new targets for novel antileukemic approaches. 1 Antibody-based therapies have focused on the membrane antigen CD33. 2, 3 Gemtuzumab ozogamicin (GO; Mylotargt; formerly CMA-676; Wyeth, Philadelphia, PA, USA) consists of a humanized IgG 4 anti-CD33 monoclonal antibody joined to N-acetyl-g-calicheamicin dimethyl hydrazide (CalichDMH). 4 In preclinical models, GO selectively and potently inhibited CD33
þ AML cell lines and primary AML cells. 5 Pivotal phase II clinical trials revealed that GO monotherapy, administered as two doses 14 days apart, induces a complete remission (CR) or CR with incomplete platelet recovery in roughly 30% of adults with relapsed CD33 þ AML. 6, 7 The major nonhematologic toxicities in those patients were infusionrelated fever, chills and hypotension, and transient liver function test abnormalities. 6, 7 GO was approved in 2000 by the United States Food and Drug Administration (FDA) for treatment of CD33
þ AML in first relapse in patients 60 years of age or older who are not considered candidates for conventional chemotherapy. 8 Subsequent clinical trials and postmarketing experience have identified potential expanded applications [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] as well as additional toxicities and limitations. [19] [20] [21] Correlative studies of patient samples and in vitro biological investigations have further characterized the roles of antigen expression, cell death pathways and resistance mechanisms in GO-induced cytotoxicity. [22] [23] [24] [25] [26] [27] [28] [29] [30] Data from some studies have prompted clinical trials incorporating cyclosporine A as a multidrug resistance modulator. [14] [15] [16] Observations from other studies have generated provocative hypotheses regarding the requirement for target cell CD33 surface expression and GO cytopathic effects. 28, 29 These latter investigations have also raised questions about the physiological relevance of selected in vitro experimental models and their translation to clinical practice. Nonetheless, the cumulative experience with GO in AML provides a valuable paradigm for the design, assessment and clinical applications of other immunoconjugates that incorporate antitumor drugs or toxins.
CD33: the target antigen
CD33, a sialic acid-dependent cell adhesion molecule, 31 is a member of the immunoglobulin superfamily subset of sialic acid binding immunoglobulin-related lectins (Siglecs; CD33 is also referred to as Siglec-3). 32 The natural ligand of CD33 and CD33's biologic function are unknown. The cytoplasmic tail has two tyrosine residues in sequences that closely resemble immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These tyrosines are phosphorylated upon pharmacological treatment (eg with pervanadate) or receptor crosslinking (eg with mouse anti-CD33 antibody plus polyclonal anti-mouse serum). When phosphorylated, these tyrosine motifs provide docking sites for recruitment and activation of Src homology-2 (SH2) domaincontaining tyrosine phosphatases (SHP-1 and SHP-2). [33] [34] [35] CD33 activation and association with SHP-1 may result in transmission of inhibitory signals, and may affect the function of neighboring membrane receptors. [34] [35] [36] Downstream steps in CD33 signaling are not well characterized, but some experimental models suggest involvement of Syk, c-Cbl, Vav and ZAP-70. 36, 37 It is unknown whether CD33 engagement by GO or other humanized therapeutic antibodies activate similar downstream signaling events in vivo or whether these events might affect internalization and intracellular trafficking of anti-CD33 immunoconjugates. However, recent in vitro studies using genetically modified myeloid cell lines show that mutations in the ITIM-like motifs impair internalization of antibody-bound CD33 and GO-induced cytotoxicity, 95 suggesting that structural and functional variations (or manipulations) altering this pathway might affect the susceptibility to anti-CD33 therapies.
Surface CD33 is normally expressed on early multilineage hematopoietic progenitors and myelomonocytic precursors. Membrane display is downregulated on granulocytes but retained on monocytes. 38, 39 The expression of CD33 on normal progenitors results in severe, but transient, myelosuppression after standard-dose GO treatment. 9 It has also been proposed, but remains unproven, that GO-associated hepatic venoocclusive disease (ie sinusoidal obstruction syndrome) results from injury to the CD33 þ liver macrophages (Kupffer cells).
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CD33 is not expressed on normal pluripotent hematopoietic stem cells; 40 therefore, neither naked anti-CD33 antibodies nor antibody conjugates ablate hematopoiesis.
Roughly 85-90% of adult and pediatric AML cases are considered 'CD33 þ ', as defined by the presence of antigen on greater than 20-25% of the leukemic blasts. 39, 41 Bone marrow cells from AML patients express between 709 and 54 894 CD33 molecules/cell (mean 10 380 molecules/cell), compared to only 859-5137 molecules/cell (mean 2997 molecules/cell) expressed by normal marrow CD33 þ cells. 42 The wide interindividual variability in AML does not correlate with cytogenetic differences. The CD33 þ /CD34 þ AML subpopulations also express somewhat higher CD33 levels (mean 9482 molecules/cell) than normal marrow CD33 þ /CD34 þ counterparts (mean 8154 molecules/cell). On average, lower levels of CD33 are found on peripheral blood CD33 þ /CD34 þ leukemic blasts (mean 7607 molecules/cell) compared to marrow blasts, 42 but systematic studies have not evaluated antigen levels on marrow and blood populations within individual patients. The significance of CD33 expression in patients treated with GO remains unclear. So far, clinical responses to single agent GO among patients with relapsed AML have not correlated with marrow blast antigen levels. 6, 7 However, it is not known whether the level might be important for de novo AML or for those receiving GO in combination with conventional or novel cytotoxic agents.
The regulation of CD33 expression on AML cells is not understood. Limited in vitro studies suggest that granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-a (IFN-a), interleukin-3 (IL-3), and IL-6 may modestly increase CD33 display on CD34 þ /CD33 þ blasts (Sivaraman et al, Blood 2002; 100: 554a; abstract). By comparison, surface expression by the AML-193 myeloid leukemic cell line is not affected by exposure to GM-CSF or IFN-g. 28 Aside from one preliminary report describing the use of G-CSF before standard dose GO for relapsed AML in elderly patients, 43 no studies have yet examined whether recombinant myeloid growth factors might improve clinical responses or induce upregulation of blast cell CD33 levels in vivo. In that pilot study, four of eight patients achieved a CR; however, five patients developed liver toxicity and three died of hepatic veno-occlusive disease. 43 Is expression of the target antigen required for a clinical response to GO or other anti-CD33 therapies? This question has been discussed because at least a portion of AML cases appear to derive from primitive leukemic stem cells that lack surface CD33 and could, therefore, escape antibody-mediated cytotoxicity. 44, 45 Given the difficulty of studying GO efficacy in those patients, this question will need to be investigated using well-designed in vitro and/or animal models. Current experience indicates, however, that treatment failure or drug resistance to GO is not commonly associated with outgrowth or selection of CD33-negative leukemia.
Another perspective on the requirement for CD33 expression relates to observations that some patients with 'CD33-negative' AML respond to GO. 28 Such observations prompted investigators in the Netherlands to study the role of CD33 in GO-induced cytotoxicity using cell lines. 28 In those studies, blocking anti-CD33 antibodies failed to prevent GO-induced lysis of CD33 þ AML-193 cells during continuous exposure to relatively high drug concentrations. By comparison, lysis was inhibited (and therefore CD33-dependent) at lower GO concentrations. GO also killed CD33-negative lymphoid leukemia cell lines in culture and inhibited their growth in NOD/SCID mice. Receptor-independent endocytosis, which could be enhanced in AML-193 cells after prestimulation with IFN-g and/or GM-CSF, appeared to account for immunoconjugate internalization and cytotoxicity in those models. 28 The clinical relevance of in vitro demonstrations of GO cytotoxicity mediated by CD33-independent mechanisms must be considered in the context of drug pharmacokinetics in patients. After the first and second 9 mg/m 2 doses of GO (administered 2 weeks apart), mean peak plasma levels (measured as hP67.6 antibody) in adults are 2.86 and 3.67 mg/ ml, respectively. 46 At this maximum tolerated dose, the majority of circulating AML blasts in most patients are nearly completely saturated with GO. 30, 47 Within 48 h after the first and second GO doses, mean plasma hP67.6 levels decrease to roughly 0.8 and 1.2 mg/ml, with half-lives of approximately 72 and 94 h. Interpatient variability in peak plasma GO levels and pharmacokinetic differences between the first and second doses relate to peripheral blood blast cell percentages, suggesting that GO is eliminated and cleared, at least in part, through CD33 binding and internalization. 46 Gender and age among adults do not affect GO pharmacokinetics. 48 The experimental model demonstrating CD33-independent lysis of AML-193 cells in the presence of GO and blocking anti-CD33 antibody required continuous exposure to drug at concentrations of X5 mg/ml for X24 h. 28 Since those conditions in culture exceed achievable plasma levels of GO, including levels after the second dose when blast cell numbers may be quite low, the model does not adequately explain why some patients with CD33-negative AML might respond to GO. Other explanations should be considered. Perhaps, 'background' levels of surface CD33 are sufficient in some cases for antigen-dependent GO uptake and cytotoxicity. Alternatively, a small, but critical, subpopulation of GO-susceptible CD33 þ leukemic progenitors might be present and therefore responsible for a cytoreductive effect. Recent in vitro observations using clinically relevant concentrations of GO with CD33-negative or minimally expressing cell lines and engineered CD33 þ sublines reinforce the concept that surface antigen expression is required for GO cytotoxicity. 95 In these studies, sublines expressing higher levels of CD33 also showed greater cell killing, suggesting that, at least in this model system with highly susceptible cell targets, antigen density correlates with drug susceptibility. 95 Clearly, additional investigations are needed to fully characterize the clinical significance of CD33 surface expression and the relevance of CD33-independent pathways of GO uptake. Further insights regarding this latter process may point to mechanisms responsible for GO-associated toxicities involving CD33-negative cells in the liver and other nonhematopoietic tissues.
An additional consideration regarding GO pharmacokinetics after standard dosing relates to the downstream effects of antibody engagement and internalization on renewed cellsurface CD33 expression. In tissue culture studies, continuous exposure to GO maintains full antibody saturation; however, it results in re-expression of only 50% of the baseline level of CD33. 30 By comparision, a brief exposure downmodulates surface antigen by a significantly lesser degree. Theoretically, a higher level of CD33 surface re-expression results in more antigen binding sites for additional drug targeting. Clinical treatment schedules that utilize more frequent 'pulse' exposures (eg using lower doses with shorter effective half-lifes) could, therefore, facilitate intracellular drug loading and augment cytotoxicity. In addition, the ability to increase blast cell GO loading might, in some cases, be important to overcome drug resistance mechanisms.
GO-induced cytotoxicity
The IgG 4 component of GO (hP67.6) is not cytotoxic in vitro 5 nor does it induce complement-mediated or antibody-dependent cellular cytotoxicity (ADCC). By comparison, the investigational HuM195 anti-CD33 antibody, which contains a human IgG 1 framework, can mediate ADCC in tissue culture but has limited cytoreductive activity when used as monotherapy in patients. 2, 49, 50 Therefore, these antibodies have been utilized primarily as vehicles to transport drugs, toxins or radioisotopes to CD33 þ leukemia cells. 9, 30, [51] [52] [53] After engagement by antibody, CD33-antibody complexes are rapidly internalized and translocated into lysosomes. 54, 55 To exploit this pathway, GO incorporates a novel bifunctional acidhydrolyzable linker that is stable at physiological pH but is efficiently cleaved in the acid environment of the lysosome. 4 Intralysosomal cleavage of GO releases the CalichDMH moiety. CalichDMH, a derivative of the enediyne antitumor antibiotic calicheamicin-g 1 , 56,57 is subsequently reduced to a highly reactive 1,4-dehydrobenzene-diradical species, presumably through the action of glutathione. [58] [59] [60] This calicheamicin diradical species positions itself within the minor groove of DNA and abstracts hydrogen atoms from the deoxyribose backbone. The resulting radicals scavenge oxygen and initiate a sequence of events that ultimately lead to site-specific and/or conformation-dependent single-and double-stranded DNA scission. 58, 61, 62 The potential cytotoxic effects of highly reactive calicheamicin diradical species on lipids, nucleic acids and/or proteins in the cytoplasm and membranes of the cell have not been well characterized. Oxidative damage might occur, indirectly, through depletion of nicotinamide adenine dinucleotide (NAD þ ). 63 Biochemical studies suggest that certain RNA sequences may also be susceptible to calicheamicin-mediated cleavage. 64 Nonapoptotic (ie necrotic) mechanisms of GOinduced cell death have been implicated in some experiments with myeloid leukemia cell lines; however, the mediators of this effect are unknown. 22 A better understanding of the roles of glutathione and other redox mediators in the activation of CalichDMH and/or mechanisms of non-nuclear cellular injury might disclose novel approaches to enhance GO cytotoxicity, including the effective use (or dangers) of combining GO with conventional chemotherapeutic agents that deplete intracellular glutathione.
Calicheamicin-g 1 stimulates a strong DNA damage response in the cell. Poly(ADP-ribose) polymerase is activated, 63 DNAdependent protein kinase (DNA-PK) activity is increased and the minor histone 2A variant, H2AX, is phosphorylated, 60, 65 suggesting activation of the ataxia-telangiectasia mutated (ATM) and/or ataxia-telangiectasia related (ATR) protein kinases. 66 Microarray studies of yeast cells indicate that calicheamicin-g 1 induces changes in transcript levels of genes involved in DNA repair and synthesis, chromatin rearrangement, cell cycle checkpoint control, nuclear proteins, ribosomal proteins, metabolic and biosynthetic genes, and proteins involved in stress response. 67 Similar analyses have not yet been reported for GO-induced cytotoxicity in human cells.
The mitochondrial pathway of apoptosis appears to be predominantly utilized for GO-induced cell death. The calicheamicin-WII derivative triggers apoptosis in a p53-independent and death receptor/FADD-independent manner via activation of mitochondrial permeability transition, cytochrome c release, and activation of caspase 9 and caspase 3. 68 The proapoptotic protein Bax is required for calicheamicin-WIIinduced cell death, whereas the antiapoptotic proteins Bcl-2 and Bcl-X L confer relative resistance. Similarly, GO treatment of primary AML cells or AML cell lines causes the loss of mitochondrial membrane potential and activation of caspase 3, while overexpression of Bcl-2 or Bcl-X L inhibits GO cytotoxicity. 26, 27 Human cells exposed to calicheamicin-g 1 for short durations undergo either permanent growth arrest and cell death or temporary arrest followed by DNA repair. 60 Accordingly, cell lines with defective DNA repair pathways are highly sensitive to calicheamicin-induced cytotoxicity. 69, 70 Continuous in vitro exposure to GO also causes G 2 /M arrest in susceptible myeloid leukemia cell lines, 22, 26 with activation of cyclin B1 and phosphorylation of checkpoint kinases 1 and 2 (Chk1 and Chk2). 26 Importantly, variable responses have been noted among primary AML cells and AML cell lines, including cell cycle arrest followed by cell death (apoptosis or necrosis), cell cycle arrest without cell death, and neither effect. 6, 22, 23, 26 Thus, multiple pathways appear to interact during GO-induced DNA damage, ultimately resulting in either cytotoxicity or survival (Figure 1) . From a therapeutic perspective, these pathways might be amenable to manipulation by agents that modulate cell cycle checkpoints and prevent DNA repair 71 or molecules that facilitate mitochondrial apoptosis. 27 
Potential mechanisms of resistance and treatment failure
Members of the ATP-binding cassette (ABC) superfamily of transporter proteins have been implicated in resistance to GO.
Figure 1
Putative cytotoxic mechanisms and cell survival pathways observed in tissue culture models using GO or calicheamicin derivatives (see text for details).
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Calicheamicins are similar in size and structure to known substrates of the multidrug resistance gp170 permeabilityglycoprotein (Pgp or MDR1 or ABCB1), 72 and early studies with these molecules revealed a modulating effect of Pgp on cytotoxicity. 73 AML blast cell Pgp expression correlated with treatment failure among patients receiving GO on the phase II clinical trials, 6 ,23 reminiscent of the negative impact of Pgp on AML response to conventional chemotherapy regimens. 74 In vitro studies have also demonstrated that Pgp-overexpressing AML cell lines and patient blast cells are resistant to GO, and that inhibitors of Pgp function can restore drug sensitivity. 22, 24 Interestingly, Pgp confers resistance to an anti-CD33 immunotoxin consisting of HuM195 linked to gelonin, a polypeptide that inactivates the 28S ribosomal subunit. 55 In this case, Pgp leads, by an unclear mechanism, to sequestration of the immunotoxin in the lysosomes where it is presumably degraded.
The observations that Pgp affects GO susceptibility in vitro and clinical responses in patients led to pilot studies incorporating cyclosporine A, a Pgp inhibitor, into GO-containing multiagent regimens. [14] [15] [16] While these trials demonstrated that GO (at reduced doses) could be safely combined with cyclosporine A, the risk of liver toxicity was increased with one combination.
14 Notably, the response rates among these patients were not superior to outcomes in larger trials using GO alone. [14] [15] [16] Multidrug resistance protein1 (MRP1 or ABCC1), which is overexpressed in 7-30% of de novo AML cases, 75 can also attenuate GO-induced cytotoxicity in cell lines and in some primary AML samples. 25 However, the effect of MRP on GOsusceptibility in Pgp þ /MRP þ co-expressing cells is demonstrable only when Pgp function is concurrently inhibited, 25 suggesting that the contribution of MRP to clinical resistance is comparatively minor. Although it is hypothesized that Pgp and MRP confer resistance by actively pumping antibody-free calicheamicin out of the cell, confirmatory tracking studies have not been done. It is possible, based on studies in other models, that the inhibitory effect against GO and calicheamicin occurs, at least for Pgp, through an antiapoptotic mechanism that is independent of drug efflux activity. 74 The ABC transporter breast cancer resistance protein (BCRP or ABCG2), which is variably expressed in AML, 76 does not confer resistance to GO. 94 Two recent lines of evidence suggest that members of the Bcl-2 family of antiapoptotic proteins are important in GO resistance. Firstly, Bcl-2 antisense oligonucleotides increase the sensitivity of HL-60 cells to GO-induced cytotoxicity (Khodadoust et al, Blood 2001; 98: 102a; abstract). Secondly, HL-60 cells with forced stable overexpression of Bcl-2 or Bcl-X L are relatively resistant to GO, and PK11195, a peripheral benzodiazepine receptor ligand that promotes mitochondrial apoptosis, increases susceptibility. 27 Probably independent of other resistance mechanisms, nonproliferative cells (ie in G 0 ) are less susceptible to in vitro GO-induced cytotoxicity, whereas activation of resting cells into cycle increases their sensitivity. 28 If cell cycle status is also important in vivo, the combination of GO with myeloid cytokines or other factors that stimulate AML blast proliferation might enhance drug sensitivity and clinical efficacy (independent of a potential cytokine effect on surface CD33 expression).
Suboptimal antibody saturation due to altered pharmacokinetics or biodistribution could, theoretically, compromise the effectiveness of GO. Indeed, large tumor burdens affect the pharmacokinetics of other antitumor antibodies. 77, 78 High circulating levels of cell-free antigen also might adsorb antibody and prevent delivery to the target cells. 79 A recent study of 92 adults who received GO for salvage therapy of AML in first relapse (a subset of the patients from the pivotal phase II clinical trials) observed a significant inverse relationship between the achievement of CR and the pretreatment peripheral blood 'CD33-antigen load'. 29 The CD33-antigen load was defined as the combined levels of maximal GO binding capacity (determined by saturation levels after in vitro incubation with GO) among the circulating AML blasts, granulocytes and monocytes. The GO binding capacity of these cells was presumably a direct reflection of membrane CD33 expression level. 30 Among six additional patients studied at 24 h after GO infusion, the CD33 sites on peripheral blood blasts were near-fully saturated (mean 92%), whereas a statistically lower mean saturation level was found among the marrow blast samples (mean 74%). Importantly, this difference was attributable to significantly lower saturation levels in two of the marrow samples that expressed extremely high CD33 antigen levels (ie roughly two-to five-fold higher than the other cases). These observations, and additional experiments showing that lower in vitro GO saturation of AML-193 cells correlates with reduced cytotoxicity, led to the proposal that a high blood CD33-antigen burden leads to a worse clinical response because GO is consumed in the periphery and less immunoconjugate is delivered to the marrow. 29 The concept that a high blood CD33 burden impairs GO delivery to the marrow is interesting and could be used as an argument for more individualized patient dosing. However, the supporting evidence is, as yet, limited, with only six patients studied. An important additional consideration is that high peripheral blood or marrow blast cell counts negatively impact the achievement of remission and survival not just to GO, 6, 7 but to virtually every chemotherapeutic agent. [80] [81] [82] Thus, factors unrelated to antigen-antibody interactions play a role in treatment failure with heavy leukemic burden. As with conventional therapy, resistance to GO is likely mediated by multiple mechanisms (Table 1) .
Conclusions and clinical perspectives
Despite the influx of new observations, further studies are needed to better define the complex interactions between surface CD33 display and GO sensitivity, immunoconjugate dosing and marrow drug levels, GO internalization kinetics and membrane CD33 renewal, biological determinants of target cell susceptibility and drug resistance, and mediators of GO-induced cell death and survival. These issues relate to current clinical observations and future applications of GO. For example, GO appears to be particularly effective as adjunctive or salvage Table 1 Potential mechanisms of resistance to GO and clinical treatment failure
Escape by CD33-negative leukemic cells 5, 22, 24, 95 or by cells with limited surface antigen renewal 28 Escape by leukemic cells in the resting (G 0 ) phase of cell cycle 28 Permeability glycoprotein (Pgp)-mediated drug efflux (major clinical relevance) [22] [23] [24] Multidrug resistance protein 1 (MRP1)-mediated drug efflux (minor clinical relevance) 25 Alterations in intracellular signaling or cell death pathways 26 Antiapoptotic effects of Bcl-2 or Bcl-X L activity 27 High circulating CD33 antigen burden leading to compromised drug delivery to marrow 29 therapy for acute promyelocytic leukemia (APL), 11, 83, 84 likely because of the relatively high, uniform expression of CD33 on APL blasts and/or the infrequent expression of Pgp and/or other resistance features. 85 Novel approaches to GO dosing should facilitate the safe and optimal use with standard APL induction or consolidation regimens. Recent and ongoing studies of adult AML are also addressing the safety and efficacy of incorporating GO into induction regimens, 17, 86, 87 postremission therapy 87, 88 and post-transplant salvage treatment. 6, 13 When used as monotherapy at the recommended dose and schedule the incidence of GO-related hepatic veno-occlusive disease is roughly 2%. 6, 89 Concern about increased toxicities in these newer settings, including prolonged severe marrow suppression and hepatic dysfunction, have led to the use of attenuated doses. 11, 87, 88 Current trials continue to investigate the potential benefit of MDR-reversal agents in augmenting GO responses. Additional studies are also warranted, based on the in vitro data summarized in this review, [26] [27] [28] [29] 95 to determine whether coadministration of GO with agents that modulate cell cycle status, DNA repair, mitochondrial pathways of apoptosis, CD33 expression, surface antigen renewal and immunoconjugate internalization might enhance efficacy in patients.
The clinical experiences and pathobiological insights with GO-and calicheamicin-induced cytotoxicity have stimulated the development of related therapeutic immunoconjugates. Recent anecdotal observations of GO responses among patients with CD33
þ acute lymphoblastic leukemia (ALL) and in vitro studies showing that primary ALL cells and ALL cell lines are highly susceptible to calicheamicin-g 1 90 paralleled the development of CMC-544, 91 which consists of CalichDMH linked to a humanized IgG 4 antibody against CD22. CD22 is a Siglec family protein and internalizing antigen that is expressed on normal and malignant B cells. 32 Preclinical studies revealed that CMC-544 potently and selectively inhibits CD22 þ B-cell lymphoma cell lines in culture and in athymic nude mouse xenografts. 91 Based on these data, CMC-544 will be evaluated in phase I clinical trials. Calicheamicin derivatives have also been conjugated to humanized antibodies against a renal cell antigen 92 and polymorphic epithelial mucin, 93 with the goal of treating renal cell carcinoma and epithelial ovarian tumors, respectively. Further progress in the testing and refinement of these agents will provide additional valuable knowledge for antibody-based treatments against other internalizing tumor antigens.
